Novartis Venture Fund Takes Aim at Japanese Bioventures (Japan)
This article was originally published in PharmAsia News
The Novartis Venture Fund, established by Swiss pharmaceutical giant Novartis, has recently been looking to invest in a number of Japanese entities. According to fund representatives, it is looking to invest in drugmakers, medical equipment manufacturers, and diagnostic drug producers. Before making any decisions, a Novartis team will determine if a start-up company has the right combination of technology and prospective products that would fulfill a market need. Asides from companies, the fund is also looking to invest in Japanese universities and research institutes with the goal of aiding them to get into business. (Click here for more - May Require Paid Subscription
You may also be interested in...
Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.